European Archives - Page 929 of 1327 - European Medical Journal

To Analyse the Incidence of Ectopic Pregnancy in Fresh Embryo Transfer Compared with Frozen-Thawed Embryo Cycles in a Tertiary Infertility Centre in India

In vitro fertilisation (IVF) is one of the major risk factors for an ectopic pregnancy (EP). Rates of EP in women undergoing IVF range from 2–5%…

The Human Species-Specific Loss of the CMAH May Explain Our Predisposition to Cardiovascular Disease

One-third of the worldwide deaths relating to cardiovascular disease (CVD), such as heart attacks and strokes are due to the accompanying atherosclerotic…

Macrophages: The New Cardiac Healing Cells?

The heart, unlike other organs, has a very limited capacity to repair which considerably contributes to heart disease being the most prevalent cause of…

The European Medical Journal Presents: EMJ Hematology 2019

Detailing some of the most important topics in haematology, EMJ Hematology 7.1 is now available.

Cell therapy takeover

Over the past year investigation into cell therapies has grown markedly, with an estimated 80% increase; the US and China are taking the lead in the development of these therapies, with Europe the closest behind.

Tagraxofusp is a Novel Targeted Therapy Directed to CD123

Blastic plasmocytoid dendritic cell neoplasm (BPDCN), a rare, highly aggressive haematologic malignancy, often with cutaneous and other extramedullary…

Review of the European Hematology Association (EHA) Congress 2019

EHA President Pieter Sonnevel welcomed the 12,614 haematology professionals to the Dutch capital, the largest number of attendees recorded…

EMJ Hematology 7.1 2019

EMJ Hematology 7.1 aims to provide you with a detailed review of the event, an account that is perfectly accompanied by a hand-picked selection of…

Rebooting the Myeloma Treatment Programme

Treatment of MM requires a multifaceted approach using a combination of therapies targeting the several pathophysiological pathways involved in the…

Post-Transplant Cyclophosphamide in HLA Matched and Haploidentical Transplant Recipients Receiving Myeloablative Timed Sequential Busulfan Conditioning Regimen: Results of a Phase II Study

The authors report a prospective Phase II trial to assess (a) if post-transplant cyclophosphamide (PTCy) could be safely incorporated in a timed…